Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Arnold DL, Sprenger T, Bar-Or A, Wolinsky JS, et al. Mult Scler 2022;28:1927-1936.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Arnold DL, Sprenger T, Bar-Or A, Wolinsky JS, et al. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Mult Scler 2022;28:1927-1936.
PMID: 35672926